Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Innovation Council · Running

FILBERT An innovative implantable device and management platform to prevent chronic fluid congestion

Coordinator
Paragate Medical Ltd, Israel
Runs
1 August 2023 to 31 July 2025
Status
Running
EU funding
€2.5m
Total cost
€4.0m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190134274

What the project is doing

In the project's own words, from its summary on CORDIS.

Pathologic fluid overload is a main clinical complication of congestive heart failure (CHF). CHF is a severe chronic disease affecting ~28 M people worldwide. Around 8 M of CHF patients are resistant to oral medications and undergo frequent hospitalizations to remove extra fluids with aggressive acute treatments, all carrying severe complications. None of these treatments can prevent fluid accumulation. The Israeli SME Paragate Medical has developed FILBERT, a unique implantable peritoneal ultrafiltration system for diuretic resistant CHF patients.

It enables 24/7 monitoring and gentle draining of extra fluids in the urinary system, preventing their accumulation. A remote treatment management platform allows physicians to continuously control patients conditions and timely adjust therapy to prevent fluid accumulation. FILBERT shifts the paradigm of fluid congestion care from the hospital to the home, improving patients quality of life and saving billions to healthcare systems.

Topics

Who is involved

OrganisationCityCountryRole
Paragate Medical LtdNazarethIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI